In vitro anti-inflammatory and antibiofilm activities of bacterial lysates from lactobacilli against oral pathogenic bacteria

Effects of probiotics, prebiotics, synbiotics and postbiotics on pediatric asthma: a systematic review

Background

Pediatric asthma, a prevalent chronic disease with rising global incidence, imposing substantial healthcare and socioeconomic burdens. Emerging evidence highlights the gut-lung axis as a pivotal therapeutic target, with microbiota dysbiosis implicated in immune dysregulation and airway hyperresponsiveness. This systematic review evaluated the efficacy and safety of probiotics, prebiotics, synbiotics, and postbiotics in pediatric asthma management.

Methods

A comprehensive search of PubMed, Cochrane library, Web of Science, and Embase was conducted up to 2nd January 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) evaluating the therapeutic use of probiotics, prebiotics, synbiotics, or postbiotics in children and/or adolescents (<18 years) with asthma.

Results

Eighteen studies (13 RCTs, n = 2,419 participants) were analyzed, focusing on children aged < 18 years. Probiotic interventions, predominantly Lactobacillus (5 studies) and Bifidobacterium (5 studies), demonstrated significant reductions in asthma exacerbations and improved pulmonary function, with strain-specific effects linked to Th2 cytokine suppression and gut-lung axis modulation. Postbiotics, including bacterial lysates (OM-85 BV, PMBL®), attenuated airway hyperresponsiveness and systemic inflammation. Synbiotics reduced viral respiratory infections and healthcare utilization. However, there is still a lack of direct RCTs to explore the therapeutic effects of prebiotics on pediatric asthma. Key limitations include methodological heterogeneity (dosing: 108-1010 CFU/day; duration: 8 weeks-12 months) and risk of bias (3 low-risk, 12 with concerns).

Conclusion

Our findings underscored the potential of microbiota-targeted therapies but highlight the need for standardized protocols, strain-specific trials, and pediatric prebiotic research. Future studies should integrate multi-omics to elucidate mechanisms and optimize personalized interventions.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD42025641318, identifier: CRD42025641318.

Lactobacillus lysates protect oral epithelial cells from pathogen-associated damage, increase secretion of pro-inflammatory cytokines and enhance barrier integrity

Periodontitis is a chronic gum disease characterised by inflammation and the loss of bone. We have explored the potential prophylactic effects of lysates from four Lactobacillus strains against the toxic effects of three periodontal pathogens (Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans). TR146 oral epithelial cells were pre-treated with Lactobacillus lysates (L. rhamnosus - GG, L. rhamnosus - SD11, L. reuteri and L. plantarum) and then challenged with pathogenic material (live cells, lysates, or supernatants). Cytokine analysis was performed on supernatants of cells treated with probiotic lysates from 1.5 h to 24 h. Effects of probiotic lysates on re-epithelialisation were determined using keratinocyte scratch assays, monitoring both migration and proliferation. Epithelial barrier function was observed after lysate addition by trans-epithelial electrical resistance (TEER) and by quantifying claudin-1 expression. Treatment of host cells with Lactobacillus lysates before pathogen exposure conferred significant protection against viability loss. Although extended pre-treatment did not generally increase protection, against live Aggregatibacter actinomycetemcomitans, significant increases in viability were seen after 24 h of pre-treatment for GG, SD11 and L. plantarum. Pro-inflammatory cytokines TNF-α, IP-10, IL-6, and IL-8 increased significantly with extended probiotic treatment, while IL-1β and IL-1α secretion significantly increased but remained constant over time. Secretion of the growth-promoting cytokine TGF-β increased after 3 h of treatment, however no increases in the regulatory cytokine IL-10 were recorded. Only exposure to SD11 significantly enhanced re-epithelialisation, TEER and claudin-1 expression while GG increased TEER but decreased claudin-1 expression. L. plantarum significantly inhibited re-epithelialisation but did not impact TEER or claudin-1 expression. All lysates significantly improved TEER in the presence of pathogenic material, demonstrating a protective effect on barrier function.

Postbiotics and Dental Caries: A Systematic Review

OBJECTIVE

This systematic review aimed to evaluate the current evidence regarding the impact of postbiotics on dental caries, focusing on the effectiveness of postbiotic interventions in caries prevention, mechanisms of action, optimal dosages, and administration protocols.

METHODS

A literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library. Eligible studies included randomized controlled trials, quasi-experimental, observational, and in vitro studies. The selection followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A qualitative synthesis was performed due to heterogeneity in study designs and outcomes.

RESULTS

Twenty-one studies were included (18 in vitro and three randomized controlled trials). Postbiotics derived from various Lactobacillus species demonstrated inhibitory effects on Streptococcus mutans growth, biofilm formation, and virulence gene expression. Proposed mechanisms include direct antimicrobial activity, inhibition of bacterial adhesion, disruption of biofilm formation, modulation of immune responses, and pH buffering. After postbiotic interventions, human trials showed reduced salivary S. mutans counts and increased salivary pH.

CONCLUSIONS

Postbiotics offer a promising novel approach to dental caries prevention by targeting cariogenic bacteria and modulating the oral microbiome through multiple mechanisms. Compared to probiotics, postbiotics present additional advantages, including enhanced safety, stability, and ease of incorporation into oral care products.

Efficacy of toothpaste containing OPTIMEALTH® OR in inhibiting dental plaque and gingivitis: A randomized controlled trial

BACKGROUND

This randomized double-blind, placebo-controlled clinical trial evaluated the effects of 2% OPTIMEALTH® OR toothpaste in regulating dental plaque microbiota and alleviating gingivitis.

METHODS

Subjects were randomly assigned to the placebo group and test group. They were instructed to brush their teeth with placebo toothpaste (placebo group) or OPTIMEALTH® OR toothpaste (test group) for a continuous 4 weeks. Clinical indices of plaque index, gingival index, and bleeding on probe (%) were examined, and images of dental plaque staining were captured at baseline and after 2 and 4 weeks. The plaque microbiome was analyzed by 16s rDNA amplicon sequencing at baseline and after 4 weeks.

RESULTS

Thirty-two participants with similar characteristics were recruited. After using OPTIMEALTH® OR toothpaste for 4 weeks, a decrease of 27.05% (P < .01), 8.29% (P > .05), and 47.44% (P < .05) in plaque index, gingival index, and bleeding on probe (%) scores was observed compared to the baseline, respectively. The extent of decline in these indices is greater than that in the placebo group. A decrease in dental plaque could be observed after 2 and 4 weeks in the test group. The 16s rDNA sequencing results showed that the observed species index and Chao index, but not the Shannon index and beta diversity, were reduced significantly after using OPTIMEALTH® OR toothpaste for 4 weeks. In addition, compared with the placebo group, using OPTIMEALTH® OR toothpaste reduced the abundance of bacterial species such as Veillonella parvula and Prevotella denticola.

CONCLUSION

Brushing teeth with 2% OPTIMEALTH® OR-fortified toothpaste could effectively reduce dental plaque and regulate plaque microbiota.

From Biofilm to Breath: The Role of Lacticaseibacillus paracasei ET-22 Postbiotics in Combating Oral Malodor

Previous studies demonstrated that sufferers with halitosis can be significantly improved with Lacticaseibacillus paracasei ET-22 (ET-22) postbiotics intervention. The objectives of this investigation were to identify the primary components responsible for inhibiting oral malodor. This study demonstrated that cell-free supernatants (CFSs) were more effective in inhibiting production of volatile sulfur compounds (VSCs). Untargeted metabolomics identified CFSs as primarily consisting of organic acids, lipids, peptides, and nucleotides. Among the potential active components, phenyllactic acid (PLA) and peptide GP(Hyp)GAG significantly inhibited microbial-induced VSCs production, with VSC concentrations reduced by 42.7% and 44.6%, respectively. Given the correlation between biofilms and halitosis, microstructural changes in biofilms were examined. PLA suppressed the biomass of the biofilm by 41.7%, while the biofilm thickness was reduced from 202.3 to 70.0 μm. GP(Hyp)GAG intervention reduced the abundance of Fusobacterium nucleatum and Streptococcus mutans within the biofilm, and the expression of biofilm-forming genes FadA and Gtfb were also suppressed by 41.8% and 59.4%. Additionally, the VSC production capacities were reduced due to the decrease in VSC producing bacteria (F. nucleatum, Prevotella intermedia, and Solobacterium moorei) and down-regulation of Cdl and Mgl genes. Collectively, the current study proved that PLA and GP(Hyp)GAG may be the main contributors to halitosis inhibition by ET-22 postbiotics.

Anti-Inflammatory Effects of Novel Probiotic Lactobacillus rhamnosus RL-H3-005 and Pedicoccus acidilactici RP-H3-006: In Vivo and In Vitro Evidence

Probiotics have garnered escalating attention in the treatment and prevention of inflammatory disorders. In this study, Lactobacillus rhamnosus RL-H3-005 (RL5) and Pediococcus acidilactici RP-H3-006 (RP6), which possess anti-inflammatory effects and favorable probiotic attributes, were selected through the comparison of an RAW264.7 inflammatory cell model screening and in vitro probiotic properties. Subsequently, it was implemented in an animal model of dextran sulfate sodium (DSS)-induced colitis. The results demonstrated that RL5 and RP6 could inhibit the release of proinflammatory factors in RAW264.7 inflammatory cells and exhibited excellent environmental adaptability, adhesion, safety, and antibacterial activity. Additionally, RL5 and RP6 provided protective effects on the intestines of mice with acute colitis by reducing the levels of intestinal inflammation and oxidative stress. Concurrently, supplementation with RL5 and RP6 modulated the composition of the gut microbiota in mice. These discoveries suggest that RL5 and RP6 can be used as a novel probiotic for alleviating intestinal inflammation.

The role of Lactobacillus plantarum in oral health: a review of current studies

Background

Oral non-communicable diseases, particularly dental caries and periodontal disease, impose a significant global health burden. The underlying microbial dysbiosis is a prominent factor, driving interest in strategies that promote a balanced oral microbiome. Lactobacillus plantarum, a gram-positive lactic acid bacterium known for its adaptability, has gained attention for its potential to enhance oral health. Recent studies have explored the use of probiotic L. plantarum in managing dental caries, periodontal disease, and apical periodontitis. However, a comprehensive review on its effects in this context is still lacking.

Aims

This narrative review evaluates current literature on L. plantarum's role in promoting oral health and highlights areas for future research.

Content

In general, the utilization of L. plantarum in managing non-communicable biofilm-dependent oral diseases is promising, but additional investigations are warranted. Key areas for future study include: exploring its mechanisms of action, identifying optimal strains or strain combinations of L. plantarum, determining effective delivery methods and dosages, developing commercial antibacterial agents from L. plantarum, and addressing safety considerations related to its use in oral care.

Lacticaseibacillus rhamnosus inhibits the development of dental caries in rat caries model and in vitro

OBJECTIVES

Dental caries result from a microbial imbalance in the oral cavity. Probiotics ecologically modulate the oral microflora to prevent caries. This study evaluated the anti-cariogenic effects of two Lacticaseibacillus rhamnosus strains in vitro and in vivo to provide a more theoretical basis for its clinical applications in caries prevention.

METHODS

In the study, cariogenic biofilms were grown with L. rhamnosus (LGG) or L. rhamnosus ATCC 7469 and analyzed. Quantitative real-time PCR (qPCR), Scanning Electron Microscope (SEM), and Confocal laser scanning microscope (CLSM) were used to detect the changes in the composition and architectures; cariogenic activity was measured by the lactic acid production and Transverse Microradiography (TMR). The effects of LGG on the 12 Sprague-Dawley rat caries model were assessed using Keyes scores and micro-CT analysis. Oral microbiome changes were evaluated through 16S rRNA gene high-throughput sequencing.

RESULTS

L. rhamnosus can reduce cariogenic bacteria in biofilm by 14.7 % to 48.9 %, with LGG exhibiting more potent inhibitory effects. Both strains of L. rhamnosus can adhere to the surface of biofilms, reduce the extracellular polysaccharides (EPS) matrix, and loosen the biofilm structure. L. rhamnosus inhibited cariogenic activity by reducing the lactic acid production in biofilms. The bovine enamel blocks presented lower mineral loss values and lesion depth values in the group Core+L.rh and Core+LGG. LGG-ingested rats had significantly lower levels of moderate dentin lesions and higher mineral density than the control group. The 16 s rRNA gene sequencing revealed that LGG regulated the beta diversity of the oral microbial community in the rat dental caries model.

CONCLUSIONS

This study revealed the promising potential of L. rhamnosus, especially the LGG strain, in the ecological prevention of dental caries.

CLINICAL SIGNIFICANCE

Probiotics may provide a strategy for preventing caries by regulating the oral microecological balance. The study revealed the promising anti-caries potential of the LGG probiotic strain in vivo and in vitro. It is expected that LGG could be used as an oral probiotic for the clinical prevention and treatment of caries.

Chemical Characterization and Effect of a Lactobacilli-Postbiotic on Streptococcus mutans Biofilm In Vitro

Postbiotic is the term used to define the soluble factors, metabolic products, or byproducts released by live probiotic bacteria or after its lysis. The objective of this study was to carry out the chemical characterization of the postbiotic of Lacticaseibacillus rhamnosus LR-32 and to evaluate its in vitro effect on the development of the Streptococcus mutans biofilm. After the cultivation of the probiotic strain, the postbiotic was extracted by centrifuging the culture and filtering the supernatant. This postbiotic was characterized by using gas chromatography coupled with mass spectrometry (GC-MS), and then it was used to determine the growth inhibition of S. mutans in its planktonic form; additionally, its effects on the following parameters in 48 h biofilm were evaluated: viable bacteria, dry weight, and gene expression of glucosyltransferases and VicR gene. The control group consisted of the biofilm without any treatment. A paired t-test was performed for statistical analysis, with the p-value set at 5%. Seventeen compounds of various chemical classes were identified in the postbiotic, including sugars, amino acids, vitamins, and acids. The treatment with the postbiotic led to an inhibition of the growth of S. mutans in its planktonic form, as well as a decrease in the number of viable bacteria, reduction in dry weight, and a negative regulation of the gene expression of gtfB, gtfC, gtfD, and vicR in its biofilm state, compared with the nontreated group (p < 0.05). The postbiotic of L. rhamnosus impaired the development of S. mutans biofilm.

Mutanolysin-Digested Peptidoglycan of Lactobacillus reuteri Promotes the Inhibition of Porphyromonas gingivalis Lipopolysaccharide-Induced Inflammatory Responses through the Regulation of Signaling Cascades via TLR4 Suppression

Periodontitis is an oral infectious disease caused by various pathogenic bacteria, such as Porphyromonas gingivalis. Although probiotics and their cellular components have demonstrated positive effects on periodontitis, the beneficial impact of peptidoglycan (PGN) from probiotic Lactobacillus remains unclear. Therefore, our study sought to investigate the inhibitory effect of PGN isolated from L. reuteri (LrPGN) on P. gingivalis-induced inflammatory responses. Pretreatment with LrPGN significantly inhibited the production of interleukin (IL)-1β, IL-6, and CCL20 in RAW 264.7 cells induced by P. gingivalis lipopolysaccharide (LPS). LrPGN reduced the phosphorylation of PI3K/Akt and MAPKs, as well as NF-κB activation, which were induced by P. gingivalis LPS. Furthermore, LrPGN dose-dependently reduced the expression of Toll-like receptor 4 (TLR4), indicating that LrPGN inhibits periodontal inflammation by regulating cellular signaling cascades through TLR4 suppression. Notably, LrPGN exhibited stronger inhibition of P. gingivalis LPS-induced production of inflammatory mediators compared to insoluble LrPGN and proteinase K-treated LrPGN. Moreover, MDP, a minimal bioactive PGN motif, also dose-dependently inhibited P. gingivalis LPS-induced inflammatory mediators, suggesting that MDP-like molecules present in the LrPGN structure may play a crucial role in the inhibition of inflammatory responses. Collectively, these findings suggest that LrPGN can mitigate periodontal inflammation and could be a useful agent for the prevention and treatment of periodontitis.

Nanoparticles of Lactiplantibacillus plantarum K8 Reduce Staphylococcus aureus Respiratory Infection and Tumor Necrosis Factor Alpha- and Interferon Gamma-Induced Lung Inflammation

Multiple studies have confirmed that Lactiplantibacillus plantarum has beneficial effects in respiratory diseases, including respiratory tract infections, asthma, and chronic obstructive pulmonary disease. However, the role of L. plantarum lysates in respiratory diseases is unclear. Staphylococcus aureus infects the lungs of mice, recruits immune cells, and induces structural changes in alveoli. Lung diseases can be further aggravated by inflammatory cytokines such as CCL2 and interleukin (IL)-6. In in vivo studies, L. plantarum K8 nanoparticles (K8NPs) restored lung function and prevented lung damage caused by S. aureus infection. They inhibited the S. aureus infection and the infiltration of immune cells and prevented the increase in goblet cell numbers in the lungs of S. aureus-infected mice. K8NPs suppressed the expression of CCL2 and IL-6, which were increased by the combination treatment of tumor necrosis factor alpha and interferon gamma (TI), in a dose-dependent manner. In in vitro studies, the anti-inflammatory effect of K8NPs in TI-treated A549 cells and TI-injected mice occurred through the reduction in activated mitogen-activated protein kinases and nuclear factor kappa-B. These findings suggest that the efficacy of K8NPs in controlling respiratory inflammation and infection can be used to develop functional materials that can prevent or alleviate respiratory diseases.

New strategies and mechanisms for targeting Streptococcus mutans biofilm formation to prevent dental caries: A review

Dental caries, a prevalent oral infectious disease, is intricately linked to the biofilm formation on the tooth surfaces by oral microbes. Among these, Streptococcus mutans plays a central role in the initiation and progression of caries due to its ability to produce glucosyltransferases, synthesize extracellular polysaccharides, and facilitate bacterial adhesion and aggregation. This leads to the formation of biofilms where the bacteria metabolize dietary carbohydrates to produce acids. Therefore, devising effective strategies to inhibit S. mutans biofilm formation is crucial for dental caries prevention and oral health promotion. Though preventive measures like mechanical removal and antibacterial drugs (fluoride, chlorhexidine) exist, they pose challenges such as time consumption, short-term effectiveness, antibiotic resistance, and disruption of oral flora balance. This review provides a comprehensive overview of emerging strategies such as antimicrobial peptides, probiotics, nanoparticles, and non-thermal plasma therapies for targeted inhibition of S. mutans biofilm formation. Moreover, current research insights into the regulatory mechanisms governing S. mutans biofilm formation are also elucidated. The objective is to foster the development of innovative, efficient and safe techniques for caries prevention and treatment, thereby expanding treatment options in clinical dentistry and promoting oral health.

Genomic DNA Extracted from Lactiplantibacillus plantarum Attenuates Porphyromonas gingivalis Lipopolysaccharide (LPS)-Induced Inflammatory Responses via Suppression of Toll-Like Receptor (TLR)-Mediated Mitogen-Activated Protein Kinase (MAPK) and Nuclear Factor-κB (NF-κB) Signaling Pathways

In the present study, we aimed to examine the inhibition of genomic DNA from Lactiplantibacillus plantarum (LpDNA) on Porphyromonas gingivalis lipopolysaccharide (PgLPS)-induced inflammatory responses in RAW264.7 cells. Pretreatment with LpDNA for 15 h significantly inhibited PgLPS-induced mRNA expression and protein secretion of interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein-1. LpDNA pretreatment also reduced the mRNA expression of Toll-like receptor (TLR)2 and TLR4. Furthermore, LpDNA inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs) and the activation of nuclear factor-κB (NF-κB) induced by PgLPS. Taken together, these findings demonstrate that LpDNA attenuates PgLPS-induced inflammatory responses by regulating MAPKs and NF-κB signaling pathways through the suppression of TLR2 and TLR4 expression.